Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

Mo Yang; Helene Vioix; Emma S Hook; Anthony J Hatswell; Rachael L Batteson; Bruce R Gaumond; Aurora O'Brate; Sanjay Popat; Paul K Paik

doi:10.1016/j.jval.2023.02.007

Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

Value Health. 2023 Aug;26(8):1155-1163. doi: 10.1016/j.jval.2023.02.007. Epub 2023 Feb 18.

Authors

Mo Yang¹, Helene Vioix², Emma S Hook³, Anthony J Hatswell³, Rachael L Batteson³, Bruce R Gaumond⁴, Aurora O'Brate², Sanjay Popat⁵, Paul K Paik⁶

Affiliations

¹ EMD Serono, Rockland, MA, USA. Electronic address: mo.yang@emdserono.com.
² The Healthcare Business of Merck KGaA, Darmstadt, Germany.
³ Delta Hat, Nottingham, England, UK.
⁴ EMD Serono, Rockland, MA, USA.
⁵ The Royal Marsden Hospital, London, England, UK.
⁶ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

Abstract

Objectives: The VISION trial showed durable activity of tepotinib in MET exon 14 (METex14) skipping non-small cell lung cancer. We analyzed health state utilities using patient-reported outcomes from VISION.

Methods: 5-level version of EQ-5D (EQ-5D-5L) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 responses were collected at baseline, every 6 to 12 weeks during treatment, and at the end of treatment and safety follow-up. EQ-5D-5L and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D) utilities were derived using United States, Canada, United Kingdom, and Taiwan value sets, where available. Utilities were analyzed with linear mixed models including covariates for progression or time-to-death (TTD).

Results: Utilities were derived for 273/291 patients (EQ-5D-5L, 1545 observations; QLU-C10D, 1546 observations). Mean (± SD) US EQ-5D-5L utilities increased after tepotinib initiation, from 0.687 ± 0.287 at baseline to 0.754 ± 0.250 before independently assessed progression, and decreased post progression (0.704 ± 0.288). US QLU-C10D utilities showed similar trends (0.705 ± 0.215, 0.753 ± 0.195, and 0.708 ± 0.209, respectively). Progression-based models demonstrated a statistically significant impact of progression on utilities and predicted higher utilities pre versus post progression. TTD-based models showed statistically significant associations of TTD with utilities and predicted declining utilities as TTD decreased. Prior treatment (yes/no) did not significantly predict utilities in progression- or TTD-based models. Utilities for Canada, United Kingdom, and Taiwan showed comparable trends.

Conclusions: In this first analysis of health state utilities in patients with METex14 skipping non-small cell lung cancer, who received tepotinib, utilities were significantly associated with progression and TTD, but not prior treatment.

Keywords: MET exon 14 skipping; MET inhibitor; disease progression; health state utilities; non-small cell lung cancer; patient-reported outcomes; tepotinib; time-to-death.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Exons
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Quality of Life
Surveys and Questionnaires

Substances

tepotinib

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States